Stargardt Disease in Childhood

See also
Status	Clinical Trial	Phase
Terminated	`NCT01676766` - Novel Quantification Methods for Fluorescence to Detect Progression in Stargardt Disease	N/A
Enrolling by invitation	`NCT06048185` - Non-interventional Long Term Follow-up Study of Participants Previously Enrolled in the STARLIGHT Study
Recruiting	`NCT04545736` - Oral Metformin for Treatment of ABCA4 Retinopathy	Phase 1/Phase 2
Recruiting	`NCT05674058` - Function and Imaging Assessments for G1961E-associated Stargardt Disease
Recruiting	`NCT06435000` - An Observational Study in Subjects to Follow the Progression of Stargardt Disease Type 1 (STGD1) Caused by Bi-Allelic Autosomal Recessive Mutations in the ABCA4 Gene
Completed	`NCT04909398` - Pupil Dynamics and Color Vision for the Detection of Eye Diseases	N/A
Completed	`NCT02255981` - Efficacy of Acupuncture in Macular Diseases	N/A
Completed	`NCT05266014` - This is a Dose-finding Study Followed by 2-year Extension Study to Evaluate Safety and Tolerability of Tinlarebant in Adolescent Subjects With Stargardt Disease	Phase 1/Phase 2
Recruiting	`NCT06467344` - Study to Evaluate ACDN-01 in ABCA4-related Retinopathy (STELLAR)	Phase 1/Phase 2
Recruiting	`NCT02435940` - Inherited Retinal Degenerative Disease Registry
Recruiting	`NCT06445322` - Prescreening Study to Identify Potential Participants for ACDN-01 Clinical Trials
Completed	`NCT05417126` - Safety and Effects of a Single Intravitreal Injection of vMCO-010 Optogenetic Therapy in Subjects With Stargardt Disease	Phase 2
Completed	`NCT03772665` - Safety and Efficacy of Emixustat in Stargardt Disease	Phase 3
Terminated	`NCT02875704` - Oxidative Stress In Stargardt Disease, Age Related Macular Degeneration and Diabetic Retinopathy
Completed	`NCT03033108` - Pharmacodynamic Study of Emixustat Hydrochloride in Subjects With Macular Atrophy Secondary to Stargardt Disease	Phase 2
Recruiting	`NCT03011541` - Stem Cell Ophthalmology Treatment Study II	N/A
Completed	`NCT02410122` - The Natural History of the Progression of Atrophy Secondary to Stargardt Disease Type 4: PROM1-Related Macular Dystrophy
Enrolling by invitation	`NCT04239625` - Open-Label Extension: Tolerability and Effects of ALK-001 on Stargardt Disease (TEASE)	Phase 2
Recruiting	`NCT05956626` - Study to Assess the Safety and Efficacy of OCU410ST for Stargardt Disease	Phase 1/Phase 2
Recruiting	`NCT02402660` - Phase 2 Tolerability and Effects of ALK-001 on Stargardt Disease	Phase 2

NCT number	NCT06377150
Study type	Observational
Source	University Hospital Tuebingen
Contact
Status	Completed
Phase
Start date	April 1, 2022
Completion date	March 31, 2024

Stargardt Disease in Childhood

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms